Pharmafile Logo

Strategy

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

NHS reports rise in prostate cancer treatments in England

Prostate Cancer UK’s risk checker has been used over a million times since its launch in February

Cell and gene therapies as depicted via a DNA strand

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Avalere Health

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

Janssen’s Tecvayli granted FDA approval for multiple myeloma

A phase 2 study demonstrated an overall response rate of 61.8% in Tecvayli-treated patients

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

- PMLiVE

Omnichannel scientific engagement and the use of archetypes to drive personalization

Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can...

Avalere Health

Springer Nature Oncologists survey report 202

[Free Report] The What, How, and When of creating content for oncologists

Create content marketing that really engages healthcare professionals.

Springer Nature

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

Patient Programmes Sponsor

Celebrating award-winning patient-centricity

Every year, Cuttsy+Cuttsy choose to sponsor 'Patient Programmes' at the PM Society Digital awards. Here's why.

Cuttsy + Cuttsy

- PMLiVE

ICR study raises possibility of predicting drug resistance in advance

The researchers found that stomach cancers could develop resistance to ATR inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links